why choose us

First received: March 21, 2023

Clinical Trial: A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors

Study Status: Completed

Recruit Status: RECRUITING

Condition: Clear Cell Renal Cell Carcinoma

Study Type: INTERVENTIONAL


Official Title: A Phase 1/2, Open-label, Multicenter, Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD70 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX131) in Adult Subjects With

Brief Summary: This is an open-label, multicenter, Phase 1/2 study evaluating the safety and efficacy of CTX131™ in subjects with relapsed or refractory solid tumors.

Read more